Trial reportThe American journal on addictions
A randomized trial of oral naltrexone for treating opioid-dependent offenders.
Trial report in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis.Frontiers in psychiatry · 2022Pooled it
- Pooled it
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Pharmacotherapy for opioid addiction in community corrections.International review of psychiatry (Abingdon, England) · 2018Pooled it
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Pharmacological interventions for drug-using offenders.The Cochrane database of systematic reviews · 2015Pooled it
- Pharmacological therapies for maintenance treatments of opium dependence.The Cochrane database of systematic reviews · 2013Pooled it
- Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.Drug and alcohol dependence · 2019Trial
- Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018Trial
- The association between medication for opioid use disorder and employment outcomes in the U.S.: The relevance of race and ethnicity.Drug and alcohol dependence reports · 2022Article
- Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell systematic reviews · 2022Article
- Italian psychiatry.International review of psychiatry (Abingdon, England) · 2018Article
- Buprenorphine Treatment for Probationers and Parolees.Substance abuse · 2015Article
- Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.British journal of clinical pharmacology · 2014Review
- Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.Journal of drug issues · 2014Article
- A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.Substance abuse · 2012Article
- Maintenance medication for opiate addiction: the foundation of recovery.Journal of addictive diseases · 2012Review
- (R)-methadone versus racemic methadone: what is best for patient care?Addiction (Abingdon, England) · 2011Article
- An Empirical Ethics Agenda for Psychiatric Research Involving Prisoners.AJOB primary research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Offenders with a history of opioid dependence are a particularly difficult group to treat. A large proportion of offenders typically relapse shortly after release from prison, commit drug-related crimes, and then are arrested and eventually re-incarcerated. Previous research demonstrated that oral naltrexone was effective in reducing opioid use and preventing recidivism among offenders under federal supervision. The 111 opioid-dependent offenders in this study were under various levels of supervision that included county and federal probation/parole, a treatment court, an alternative disposition program, and an intermediate punishment program. Subjects were randomly assigned to receive 6 months of either 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56) or standard psychosocial treatment as usual (TAU) without naltrexone (n = 55). While the TAU subjects who remained in treatment used more opioids than the naltrexone subjects who remained, the high dropout rate for both groups made it difficult to assess the effectiveness of naltrexone. The study provides limited support for the use of oral naltrexone for offenders who are not closely monitored by the criminal justice system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.